Rare EMA-Sanctioned Compassionate Use Program Sends Gilead’s Sofosbuvir To Market Early
This article was originally published in The Pink Sheet Daily
Gilead Sciences sofosbuvir for hepatitis C has gained early, but restricted, entry into the EU market as the European Medicines Agency allows compassionate use at Sweden’s request.
You may also be interested in...
CTI’s conditional EU approval for its non-Hodgkin B-cell lymphoma drug Pixuvri goes against the run of the drug in the US, but reinforces the idea that staggered approvals are on the way in Europe.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.